Related references
Note: Only part of the references are listed.Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow
Giuseppe Basso et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz et al.
BLOOD (2008)
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival:: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Moericke et al.
BLOOD (2008)
Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: Insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster-based chemotherapy
Maurizio Arico et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia
T. Flohr et al.
LEUKEMIA (2008)
Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
E. Fronkova et al.
LEUKEMIA (2008)
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
Jianbiao Zhou et al.
BLOOD (2007)
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
Kirk R. Schultz et al.
BLOOD (2007)
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Albert Moghrabi et al.
BLOOD (2007)
Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: Results from ALL-BFM 90 and 95
Andre Schrauder et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Drug therapy - Treatment of acute lymphoblastic leukemia
CH Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study
A Balduzzi et al.
LANCET (2005)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
JJM van Dongen et al.
LEUKEMIA (2003)
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II
M Aricò et al.
BLOOD (2002)
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL
MJ Willemse et al.
BLOOD (2002)
Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome
C Nyvold et al.
BLOOD (2002)
Precursor-B-ALL with DH-JH gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14
T Szczepanski et al.
LEUKEMIA (2001)
Minimal residual disease in leukaemia patients
Tomasz Szczepanski et al.
LANCET ONCOLOGY (2001)
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995
M Schrappe et al.
LEUKEMIA (2000)
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995
V Conter et al.
LEUKEMIA (2000)
Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia
M Aricò et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
